Systemic CD4 immunity as a key contributor to PD-L1/PD-1 blockade immunotherapy efficacy
M Zuazo, H Arasanz, A Bocanegra… - Frontiers in …, 2020 - frontiersin.org
PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for
several cancer types compared to conventional cytotoxic therapies. However, the specific …
several cancer types compared to conventional cytotoxic therapies. However, the specific …